Prostate Cancer Gene Marker Panel for Biopsy Risk Stratification
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diagnostic tests for prostate cancer are inadequate in accurately distinguishing between benign and malignant tumor types, leading to unnecessary treatments and failing to reliably identify clinically significant prostate cancer, particularly Grade Group ≥2 prostate cancer, due to their lack of specificity and invasiveness.
Innovation Solution
Assaying the expression levels of TMPRSS2-ERG, SCHLAP1, OR51E2, PCAT14, PCA3, and KLK4 genes, optionally with APOC1, in a sample from a subject to identify high-grade prostate cancer and administer targeted treatment, and using these markers to generate a diagnostic score for prostate cancer prognosis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If current diagnostic tests (PSA, MRI) are used to detect prostate cancer, then screening coverage is achieved, but diagnostic accuracy and specificity are insufficient leading to false positives and unnecessary biopsies
Solution Approach 1:
The diagnostic approach is segmented into multiple independent gene marker assessments (TMPRSS2-ERG, SCHLAP1, OR51E2, PCAT14, PCA3, KLK4, APOC1) rather than relying on a single test. Each marker provides specific information about different aspects of prostate cancer biology, and their combined evaluation enables more precise risk stratification and reduces false positives
Solution Approach 2:
The invention changes the diagnostic parameter from traditional PSA levels or MRI findings to gene expression levels and fusion events. By measuring mRNA expression levels of specific genes and detecting gene fusions at the molecular level, the test achieves higher diagnostic accuracy and specificity for clinically significant prostate cancer
2Reliability
If invasive biopsy is performed to confirm prostate cancer diagnosis, then definitive diagnosis is obtained, but patient morbidity and treatment costs increase
Solution Approach 1:
The gene expression profile test serves as an intermediary diagnostic tool between initial screening (PSA/MRI) and invasive biopsy. By providing highly specific molecular evidence of clinically significant prostate cancer through gene markers, the test enables clinicians to confidently proceed to or avoid biopsy based on risk stratification, reducing unnecessary invasive procedures while maintaining diagnostic reliability
Solution Approach 2:
The non-invasive gene expression test is performed as a preliminary assessment before deciding on invasive biopsy. By evaluating multiple gene markers upfront, the test pre-identifies patients at high risk for clinically significant cancer who truly need biopsy, while sparing low-risk patients from unnecessary invasive procedures
3Measurement precision
If multiple gene markers are assayed to improve diagnostic accuracy, then detection precision increases, but test complexity and cost increase
Solution Approach 1:
Multiple gene marker assessments (TMPRSS2-ERG fusion, SCHLAP1, OR51E2, PCAT14, PCA3, KLK4, APOC1) are merged into a single integrated gene expression profile test. By combining these markers in one assay platform, the invention achieves high detection precision for clinically significant prostate cancer while avoiding the need for multiple separate tests, thereby controlling overall test complexity
Data Source
AI summary
Provided herein are kits and methods useful for cancer diagnosis, prognosis, research and therapy. In particular, provided herein are methods of diagnosing, prognosing, and/or treating prostate cancer based on expression levels of cancer markers.